Apyx Medical
Medical · 435 employees
Apyx Medical is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for our Renuvion® and J-Plasma® helium plasma technologies, we’re focused on one thing: bringing transformative solutions to the customers we serve. Apyx, formerly Bovie® Medical, leverages deep expertise and decades of experienc
Funding history
- Series public offering — $10.0M — Nov 2025
Recent signals
- May 11, 2026: SEC 8-K (8.01): On May 11, 2026, Apyx Medical Corporation announced via press release that it has received expanded 510(k) clearance from the U.S. Food and Drug Administration for its AYON Body Contouring System to include power liposuction. This regulatory approval is significant as it broadens the product's capabilities, potentially enhancing its market position in the body contouring space and offering new treatment options to customers. The approval date is crucial as it indicates the event's recency and relevance for investors and stakeholders.
- Nov 19, 2025: Raised $10.0M in Series public offering
- Nov 17, 2025: SEC 8-K (1.01): On November 18, 2025, Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets, LLC, to issue and sell 2,762,431 shares of common stock at an offering price of $3.62 per share. Additionally, the Company granted the Underwriter an option to issue and sell up to 414,365 additional shares. The offering closed on November 19, 2025, resulting in aggregate gross proceeds for the Company. This transaction enhances the Company’s capital position to possibly fund future growth initiatives and operational activities.
- Nov 28, 2023: Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer
See plans & pricing → Track Apyx Medical’s funding, hiring, and signals — with verified contacts — on Fundz.